Article
PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia.
Cancer discovery - 1 Jan 2022
Li Jianping, Hlavka-Zhang Julia, Shrimp Jonathan H, Piper Crissandra, Dupéré-Richér Daphne, Roth Jacob S, Jing Duohui, Casellas Román Heidi L, Troche Catalina, Swaroop Alok, Kulis Marta, Oyer Jon A, Will Christine M, Shen Min, Riva Alberto, Bennett Richard L, Ferrando Adolfo A, Hall Matthew D, Lock Richard B, Licht Jonathan D
Abstract excerpt
Mutations in epigenetic regulators are common in relapsed pediatric acute lymphoblastic leukemia (ALL). Here, we uncovered the mechanism underlying the relapse of ALL driven by an activating mutation of the NSD2 histone methyltransferase (p.E1099K). Using high-throughput drug screening, we found that NSD2-mutant cells were specifically resistant to glucocorticoids. Correction of this mutation restored...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.